IP Library Granted Patent US 7,605,262
Granted Patent B2
US 7,605,262 · App. 12/016,926 · Granted Oct 20, 2009

Podophyllotoxin derivatives

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,605,262
App. No.
12/016,926
Granted
Oct 20, 2009
Kind
B2
Abstract

4-O esters of podophyllotoxin and 4′-demethylepipodophyllotoxin are provided. The compounds are 4-O esters of an alkanoic acid or substituted alkanoic acid and podophyllotoxin and 4′-demethylepipodophyllotoxin. The compounds are useful for treating cancer.

Claims (80)

1. A compound represented by the formula:

wherein

R is C(O)—R 1 , and

R 1 is

R 2 is hydrogen, PO 3 H 2 or PO(OR 3 ) 2 where R 3 is benzyl;

R 22 is hydrogen, halo, lower alkyl, lower alkoxy, hydroxy, R 40 C(O)O, cyano, nitro, amino, halogenated lower alkyl, halogenated lower alkoxy, hydroxycarbonyl, formyl, lower alkoxycarbonyl, tri lower alkylsilyl, lower alkylcarbonyloxy, lower alkylcarbonylamino, lower alkylcarbonyloxymethyl, substituted vinyl, 1-hydroxy-2-nitroethyl, alkoxycarbonylethyl, aminocarbonyl, mono- or di-alkylcarbonyl, alkylcarbonylmethyl, benzoylmethyl, benzylcarbonyloxymethyl, or mono- or di lower alkoxymethyl;

R 23 is hydrogen, halo, lower alkyl, lower alkoxy, hydroxy, R 40 C(O)O, cyano, nitro, amino, halogenated lower alkyl, halogenated lower alkoxy, hydroxycarbonyl, formyl, lower alkoxycarbonyl, CH 2 NR 27 R 28 (where each of R 27 and R 28 is independently H—, alkyl of 1-6 carbons, optionally substituted phenyl, hydroxy lower alkyl, amino lower alkyl, or mono- or dialkylamino lower alkyl, or R 27 and R 28 taken together with —N— represent a cyclic amino-), CH 2 R 29 (where R 29 is lower alkoxy, CN, amino lower alkoxy, mono- or di-lower alkylamino lower alkoxy, lower alkylthio, amino lower alkylthio, or mono- or di-lower alkylamino lower alkylthio), or NR 30 R 31 (where each of R 30 and R 31 is independently hydrogen, lower alkyl, phenyl, hydroxy lower alkyl, amino lower alkyl, or mono- or di-lower alkyl, or R 30 and R 31 taken together with —N— represent a cyclic amino), dialkylamino alkyl, lower alkylcarbonyloxy, or lower alkylcarbonylamino;

R 24 is hydrogen, halo, lower alkyl, lower alkoxy, hydroxy, R 40 C(O)O, cyano, nitro, amino, amino lower alkyl, halogenated lower alkyl, halogenated lower alkoxy, hydroxycarbonyl, formyl, lower alkoxycarbonyl, carbamoyloxy, lower alkylcarbonyloxy, or lower alkylcarbonylamino, or R 24 together with R 25 is methylenedioxy;

R 25 is hydrogen, halo, lower alkyl, lower alkoxy, hydroxy, R 40 C(O)O, cyano, nitro, amino, halogenated lower alkyl, halogenated lower alkoxy, hydroxycarbonyl, formyl, lower alkoxycarbonyl, lower alkylcarbonyloxy, or lower alkylcarbonylamino; and

R 26 is hydrogen, halo, lower alkyl, lower alkoxy, hydroxy, R 40 C(O)O, cyano, nitro, amino, halogenated lower alkyl, halogenated lower alkoxy, hydroxycarbonyl, formyl, lower alkoxycarbonyl, lower alkylcarbonyloxy, or lower alkylcarbonylamino;

R 40 is R 41 —O—(CH 2 ) s —;

s is an integer of 1-10;

R 41 is selected from the group consisting of lower alkyl;

phenyl optionally substituted with from one to five sub stituents independently selected from the group consisting of halo, lower alkyl, lower alkoxy, hydroxy, cyano, nitro, amino, halogenated lower alkyl, halogenated lower alkoxy, formyl, lower alkyl carbonyl, hydroxycarbonyl, lower alkylcarbonyloxy, benzyloxy, optionally substituted piperazino, lower alkoxycarbonyl, and lower alkylcarbonylamino;

cycloalkyl of 3-7 carbons, optionally substituted with one to five substituents independently selected from the group consisting of halo, lower alkyl, lower alkoxy, hydroxy, cyano, nitro, amino, halogenated lower alky, halogenated lower alkoxy, hydroxycarbonyl, lower alkoxycarbonyl, lower alkylcarbonyloxy, and lower alkylcarbonylamino;

a fused, 2-, 3-, or 4-ring heterocyclic system optionally substituted with one to five substituents independently selected from the group consisting of halo, lower alkyl, lower alkoxy, hydroxy, cyano, nitro, amino, halogenated lower alkyl, halogenated lower alkoxy, hydroxycarbonyl, lower alkoxycarbonyl, lower alkylcarbonyloxy, and lower alkylcarbonylamino;

1- or 2-naphthyl optionally substituted with from one to four substituents independently selected from the group consisting of halo, lower alkyl, lower alkoxy, hydroxy, cyano, nitro, amino, halogenated lower alkyl, halogenated lower alkoxy, hydroxycarbonyl, lower alkoxycarbonyl, lower alkylcarbonyloxy, and lower alkylcarbonylamino; and

a 5 or 6 membered heterocyclic ring containing one or two nitrogen atoms, which ring is optionally substituted with one or two substituents selected from the group consisting of halo, lower alkyl, lower alkoxy, hydroxy, cyano, nitro, amino, halogenated lower alkyl, halogenated lower alkoxy, hydroxycarbonyl, lower alkoxycarbonyl, lower alkylcarbonyloxy, and lower alkylcarbonylamino;

wherein the wavy line represents the point of connection to C(O).

2. The compound of claim 1 , wherein

R 22 is hydrogen;

R 23 is CH 2 NR 27 R 28 (where each of R 27 and R 28 is independently H—, alkyl of 1-6 carbons, optionally substituted phenyl, hydroxy lower alkyl, amino lower alkyl, or mono- or dialkylamino lower alkyl, or R 27 and R 28 taken together with —N— represent a cyclic amino-), NR 30 R 31 (where each of R 30 and R 31 is independently hydrogen, lower alkyl, phenyl, hydroxy lower alkyl, amino lower alkyl, or mono- or di-lower alkyl, or R 30 and R 31 taken together with —N— represent a cyclic amino), or dialkylamino alkyl;

R 24 is selected from the grout consisting of lower alkoxy, hydroxy, halogenated lower alkyl, halogenated lower alkoxy, hydroxycarbonyl, formyl, lower alkoxycarbonyl, carbamoyloxy, and lower alkylcarbonyloxy, or R 24 together with R 25 is methylenedioxy;

R 25 is hydrogen, or together with R 24 is methylenedioxy;

R 26 is hydrogen.

3. The compound of claim 2 , wherein R 23 is CH 2 NR 27 R 28 (where each of R 27 and R 28 is lower alkyl), R 25 is hydrogen, and R 24 is hydroxy, alkoxy or alkylcarbonyloxy.

4. The compound of claim 3 , wherein R 23 is CH 2 N(CH 3 ) 2 and R 24 is hydroxy.

5. The compound of claim 1 , wherein

R 22 is hydrogen, lower alkyl, or halogenated lower alkyl;

R 23 is hydrogen or lower alkyl;

R 24 is selected from the group consisting of lower alkoxy, hydroxy, halogenated lower alkoxy, carbamoyloxy, and lower alkylcarbonyloxy, or R 24 together with R 25 is methylenedioxy;

R 25 is hydrogen, or together with R 24 is methylenedioxy; and

R 26 is hydrogen.

6. The compound of claim 5 , wherein R 23 is hydrogen, R 25 is hydrogen, and R 24 is carbamoyloxy.

7. The compound of claim 5 , wherein R 22 is lower alkyl and R 24 is 4-(1-piperidino)-1-piperidinocarbonyloxy.

8. The compound of claim 7 , wherein R 22 is ethyl.

9. The compound of claim 1 , wherein

R 22 is lower alkyl;

R 23 is hydrogen;

R 24 is selected from the group consisting of hydroxy, lower alkoxy, halogenated lower alkoxy, hydroxycarbonyl, formyl, lower alkoxycarbonyl, carbamoyloxy, and lower alkylcarbonyloxy;

R 25 is hydrogen; and

R 26 is hydrogen.

10. The compound of claim 9 , wherein R 22 is ethyl and R 24 is hydroxy.

11. The compound of claim 1 , wherein

each of R 22 , R 24 , R 25 , and R 26 is hydrogen; and

R 23 is amino or nitro.

12. The compound of claim 11 , wherein R 23 is amino.

13. The compound of claim 12 , wherein R 23 is nitro.

14. The compound of claim 1 , wherein

R 22 is tri-lower alkylsilyl;

R 23 is hydrogen;

R 24 is selected from the group consisting of hydroxy, lower alkoxy, halogenated lower alkoxy, hydroxycarbonyl, formyl, lower alkoxycarbonyl, carbamoyloxy, and lower alkylcarbonyloxy;

R 25 is hydrogen; and

R 26 is hydrogen.

15. The compound of claim 14 , wherein R 22 is t-butyldimethylsilyl and R 24 is hydroxy.

16. A compound of claim 1 , selected from:

or a pharmaceutically acceptable salt thereof

17. A compound of claim 1 represented by the formula:

wherein

R is C(O)—R 1 , and

R 1 is

R 22 is hydrogen, halo, lower alkyl, lower alkoxy, hydroxy, R 40 C(O)O, cyano, nitro, amino, halogenated lower alkyl, halogenated lower alkoxy, hydroxycarbonyl, formyl, lower alkoxycarbonyl, tri lower alkylsilyl, lower alkylcarbonyloxy, lower alkylcarbonylamino, lower alkylcarbonyloxymethyl, substituted vinyl, 1-hydroxy-2-nitroethyl, alkoxycarbonylethyl, aminocarbonyl, mono- or di-alkylcarbonyl, alkylcarbonylmethyl, benzoylmethyl, benzylcarbonyloxymethyl, or mono- or di lower alkoxymethyl;

R 23 is hydrogen, halo, lower alkyl, lower alkoxy, hydroxy, R 40 C(O)O, cyano, nitro, amino, halogenated lower alkyl, halogenated lower alkoxy, hydroxycarbonyl, formyl, lower alkoxycarbonyl, CH 2 NR 27 R 28 (where each of R 27 and R 28 is independently H—, alkyl of 1-6 carbons, optionally substituted phenyl, hydroxy lower alkyl, amino lower alkyl, or mono- or dialkylamino lower alkyl, or R 27 and R 28 taken together with —N— represent a cyclic amino-), CH 2 R 29 (where R 29 is lower alkoxy, CN, amino lower alkoxy, mono- or di-lower alkylamino lower alkoxy, lower alkylthio, amino lower alkylthio, or mono- or di- lower alkylamino lower alkylthio), or NR 30 R 31 (where each of R 30 and R 31 is independently hydrogen, lower alkyl, phenyl, hydroxy lower alkyl, amino lower alkyl, or mono- or di-lower alkyl, or R 30 and R 31 taken together with —N— represent a cyclic amino), dialkylamino alkyl, lower alkylcarbonyloxy, or lower alkylcarbonylamino;

R 24 is hydrogen, halo, lower alkyl, lower alkoxy, hydroxy, R 40 C(O)O, cyano, nitro, amino, amino lower alkyl, halogenated lower alkyl, halogenated lower alkoxy, hydroxycarbonyl, formyl, lower alkoxycarbonyl, carbamoyloxy, lower alkylcarbonyloxy, or lower alkylcarbonylamino, or R 24 together with R 25 is methylenedioxy;

R 25 is hydrogen, halo, lower alkyl, lower alkoxy, hydroxy, R 40 C(O)O, cyano, nitro, amino, halogenated lower alkyl, halogenated lower alkoxy, hydroxycarbonyl, formyl, lower alkoxycarbonyl, lower alkylcarbonyloxy, or lower alkylcarbonylamino; and

R 26 is hydrogen, halo, lower alkyl, lower alkoxy, hydroxy, R 40 C(O)O, cyano, nitro, amino, halogenated lower alkyl, halogenated lower alkoxy, hydroxycarbonyl, formyl, lower alkoxycarbonyl, lower alkylcarbonyloxy, or lower alkylcarbonylamino;

R 40 is R 41 —O—(CH 2 ) s —;

s is an integer of 1-10;

R 41 is selected from the group consisting of:

lower alkyl;

phenyl optionally substituted with from one to five substituents independently selected from the group consisting of halo, lower alkyl, lower alkoxy, hydroxy, cyano, nitro, amino, halogenated lower alkyl, halogenated lower alkoxy, formyl, lower alkyl carbonyl, hydroxycarbonyl, lower alkylcarbonyloxy, benzyloxy, optionally substituted piperazino, lower alkoxycarbonyl, and lower alkylcarbonylamino;

cycloalkyl of 3-7 carbons, optionally substituted with one to five substituents independently selected from the group consisting of halo, lower alkyl, lower alkoxy, hydroxy, cyano, nitro, amino, halogenated lower alky, halogenated lower alkoxy, hydroxycarbonyl, lower alkoxycarbonyl, lower alkylcarbonyloxy, and lower alkylcarbonylamino;

a fused, 2-, 3-, or 4-ring heterocyclic system optionally substituted with one to five substituents independently selected from the group consisting of halo, lower alkyl, lower alkoxy, hydroxy, cyano, nitro, amino, halogenated lower alkyl, halogenated lower alkoxy, hydroxycarbonyl, lower alkoxycarbonyl, lower alkylcarbonyloxy, and lower alkylcarbonylamino;

1- or 2-naphthyl optionally substituted with from one to four sub stituents independently selected from the group consisting of halo, lower alkyl, lower alkoxy, hydroxy, cyano, nitro, amino, halogenated lower alkyl, halogenated lower alkoxy, hydroxycarbonyl, lower alkoxycarbonyl, lower alkylcarbonyloxy, and lower alkylcarbonylamino; and

a 5 or 6 membered heterocyclic ring containing one or two nitrogen atoms, which ring is optionally substituted with one or two substituents selected from the group consisting of halo, lower alkyl, lower alkoxy, hydroxy, cyano, nitro, amino, halogenated lower alkyl, halogenated lower alkoxy, hydroxycarbonyl, lower alkoxycarbonyl, lower alkylcarbonyloxy, and lower alkylcarbonylamino;

wherein the wavy line represents the point of connection to C(O).

18. A compound of claim 17 , which compound is:

or a pharmaceutically acceptable salt thereof.

19. The compound of any one of claims 1 - 16 , 17 and 18 in combination with a pharmaceutically-acceptable excipient to form a pharmaceutical composition.

20. The pharmaceutical composition of claim 19 , which is in the form of a liposomal composition.

Assignments (4)
CONFIRMATORY LICENSE Recorded Nov 23, 2011
From: CALIFORNIA PACIFIC MEDICAL CENTER RESEARCH INSTITUTE
To: US ARMY, SECRETARY OF THE ARMY
Reel/Frame 027278/0802 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 29, 2009
From: YANG, LI-XI
To: CALIFORNIA PACIFIC MEDICAL CENTER; CATHOLIC HEALTHCARE WEST DBA ST. MARY'S MEDICAL CENTER OF SAN FRANCISCO
Reel/Frame 023715/0207 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE'S ADDRESS FROM 475 BRANNAN STREET, SUITE 200, SAN FRANCISCO, CA 94107 PREVIOUSLY RECORDED ON REEL 023180 FRAME 0332. ASSIGNOR(S) HEREBY CONFIRMS THE CORRECT ASSIGNEE'S ADDRESS TO BE 475 BRANNAN STREET, SUITE 220, SAN FRANCISCO, CA 94107. Recorded Dec 29, 2009
From: CALIFORNIA PACIFIC MEDICAL CENTER
To: SUTTER WEST BAY HOSPITALS, DBA CALIFORNIA PACIFIC MEDICAL CENTER
Reel/Frame 023715/0749 →
CHANGE OF NAME Recorded Sep 2, 2009
From: CALIFORNIA PACIFIC MEDICAL CENTER
To: SUTTER WEST BAY HOSPITALS, DBA CALIFORNIA PACIFIC MEDICAL CENTER
Reel/Frame 023180/0332 →